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α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic	acid–type	(AMPA-type)	glutamate	receptors	(AMPARs)	
play	an	important	role	in	plasticity	at	central	synapses.	Although	there	is	anatomical	evidence	for	AMPAR	
expression	in	the	peripheral	nervous	system,	the	functional	role	of	such	receptors	in	vivo	is	not	clear.	To	
address	this	issue,	we	generated	mice	specifically	lacking	either	of	the	key	AMPAR	subunits,	GluA1	or	GluA2,	
in	peripheral,	pain-sensing	neurons	(nociceptors),	while	preserving	expression	of	these	subunits	in	the	central	
nervous	system.	Nociceptor-specific	deletion	of	GluA1	led	to	disruption	of	calcium	permeability	and	reduced	
capsaicin-evoked	activation	of	nociceptors.	Deletion	of	GluA1,	but	not	GluA2,	led	to	reduced	mechanical	
hypersensitivity	and	sensitization	in	models	of	chronic	inflammatory	pain	and	arthritis.	Further	analysis	
revealed	that	GluA1-containing	AMPARs	regulated	the	responses	of	nociceptors	to	painful	stimuli	in	inflamed	
tissues	and	controlled	the	excitatory	drive	from	the	periphery	into	the	spinal	cord.	Consequently,	peripher-
ally	applied	AMPAR	antagonists	alleviated	inflammatory	pain	by	specifically	blocking	calcium-permeable	
AMPARs,	without	affecting	physiological	pain	or	eliciting	central	side	effects.	These	findings	indicate	an	
important	pathophysiological	role	for	calcium-permeable	AMPARs	in	nociceptors	and	may	have	therapeutic	
implications	for	the	treatment	chronic	inflammatory	pain	states.
Introduction
Chronic pain represents a frequent and poorly understood medical 
problem. Plasticity of synaptic transmission in the nervous system 
following inflammation in peripheral organs or nerve injury is an 
important component of the cellular basis of chronic, pathological 
pain (1). Glutamate serves as the primary excitatory neurotrans-
mitter at several key synapses in the somatosensory nociceptive 
pathway, in which it activates both ionotropic and metabotropic 
receptors. Recently, the α-amino-3-hydroxy-5-methyl-4-isoxazole-
propionic acid–type (AMPA-type) glutamate receptors (AMPARs) 
have emerged as important mediators of synaptic plasticity in the 
brain (2, 3). In contrast to NMDA-type glutamate receptors, which 
always permit Ca2+ entry upon activation, AMPARs constitute an 
activity-dependent switch, which controls glutamate-evoked entry 
of Ca2+ into neurons (4). This activity-dependent switch is brought 
about by regulated expression and inclusion of the subunit GluA2 
(ref. 5; previously called GluR-B or GluR2), which imparts low Ca2+ 
permeability to AMPAR channels (3, 4). In contrast, the GluA1 
subunit (previously called GluR-A or GluR1) is highly expressed 
in regions that demonstrate a high density of calcium-permeable 
AMPARs, including components of pain pathways (5–7). Although 
our previous studies in global gene knockouts of AMPAR subunits 
revealed an important role for GluA1-containing AMPARs in 
chronic pain mechanisms (6), they did not identify the anatomi-
cal venue involved. Indeed, AMPARs are expressed across several 
key modulatory regions in the somatosensory pathways mediating 
pain, such as peripheral nociceptive neurons, spinal dorsal horn, 
ventral horn, and in several brain regions (5–8), which govern the 
sensory, affective, and emotional components of pain. However, the 
differential, relative contributions of these regions toward central 
sensitization and chronic pain have so far not been elucidated.
All peripheral sensory neurons use glutamate as their primary 
transmitter, and major subsets of sensory neurons of the dorsal 
root ganglia (DRG) are known to express mRNA or show immu-
noreactivity for ionotropic and metabotropic glutamate recep-
tors. Electron microscopy studies provided compelling evidence 
that AMPAR subunits are transported into peripheral processes 
of sensory neurons (e.g., ref. 8), and recent anatomical and ex vivo 
electrophysiological data have also suggested presynaptic local-
ization and functional involvement of AMPAR subunits in spi-
nal terminals (9, 10). However, the functional roles of AMPARs 
situated on central and peripheral terminals of sensory neurons in 
nociceptive modulation in vivo, at the level of the whole organism, 
have remained unclear. Furthermore, because AMPARs are also 
expressed in peripheral sympathetic neurons, Schwann cells, and 
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keratinocytes (11), the use of pharmacological agents alone does 
not fully permit the dissection of AMPAR contribution at different 
loci in the modulation of pain in vivo.
Here, we have used the Cre-loxP system (12) to generate trans-
genic mice that selectively lack the key AMPAR subunits, GluA1 
or GluA2, specifically in the peripheral arm of the somatosen-
sory pain pathway, i.e., in the soma, axons, and the peripheral 
and central terminals of nociceptive neurons of the DRG, leaving 
the AMPAR in the central nervous system intact. A combination 
of electrophysiologic, pharmacologic, and genetic approaches 
revealed that GluA1-containing, GluA2-lacking calcium-perme-
able AMPARs modulate responses of peripheral nociceptors to 
algogens. Furthermore, we observed that calcium-permeable 
AMPARs play distinct roles in physiological (i.e., noninjured) 
and postinflammatory states. In contrast, GluA2-containing cal-
cium-impermeable AMPARs, which can be heteromers of GluA2 
with GluA1, GluA3, or GluA4, in nociceptors were found to be 
dispensable for pain modulation. Our results demonstrate that 
GluA1-containing AMPARs expressed in peripheral nociceptive 
neurons are important modulators of peripheral sensitization as 
well as peripheral mechanisms triggering central hyperexcitability 
in inflammatory states and represent what we believe to be novel 
targets for pain therapeutics.
Results
SNS-Cre–mediated conditional deletion of GluA1 or GluA2 specifically 
in peripheral nociceptive neurons. We have previously reported that 
a mouse line expressing the Cre recombinase under control of 
the Nav1.8 promoter (SNS-Cre) enables conditional gene deletion 
specifically in peripheral nociceptive neurons in the DRG, while 
leaving the expression in central nervous system and nonneural 
cells intact (e.g., refs. 13, 14). Accordingly, we generated mice lack-
ing GluA1 or GluA2 specifically in peripheral nociceptive neurons 
(SNS-GluA1–/– and SNS-GluA2–/– mice, respectively) via Cre/loxP-
mediated recombination by mating SNS-Cre mice with mice 
carrying the floxed Gria1 allele (GluA1fl/fl; ref. 15) or Gria2 allele 
(GluA2fl/fl; ref. 16) (Figure 1, A and B). An anti-GluA1 antibody 
showed widespread immunoreactivity in small-diameter as well 
as large-diameter neurons of adult mouse DRG, consistent with a 
previous report on neonatal rat DRG (9), but showed a complete 
lack of staining in DRG, spinal cords, and brains derived from clas-
sical (global) deletion mutants of GluA1, thereby demonstrating 
its specificity (Figure 1A). Using this antibody, we found that only 
large-diameter neurons of the DRG in SNS-GluA1–/– mice, which 
mostly represent somata of tactile afferents and proprioceptors, 
continued to show GluA1 expression. In contrast, anti-GluA1 
immunoreactivity was markedly reduced in small-diameter neu-
rons, a majority of which constitute somata of C- and A-δ nocicep-
tors (typical examples in Figure 1A and size-frequency analysis in 
Figure 1C). This was supported by a specific expression of the Cre 
recombinase in small-sized neurons of the DRG in SNS-GluA1–/– 
mice, as judged via anti-Cre immunoreactivity (Figure 1A). Dual 
immunohistochemistry using anti-GluA1 and anti-calcitonin 
gene-related peptide (CGRP) antibodies (markers of peptidergic 
nociceptive neurons) or isolectin-B4 (IB4; a marker for nonpepti-
dergic nociceptors) indicated a selective deletion of anti-GluA1 
immunoreactivity in nociceptors of SNS-GluA1–/– mice, whereas 
large-diameter neurons negative for CGRP expression/IB4 binding 
retained expression of GluA1 (a quantitative summary is shown 
in Figure 1E and typical examples are shown in Supplemental 
Figure 1; supplemental material available online with this article; 
doi:10.1172/JCI44911DS1). In contrast, GluA1 expression was 
preserved in the spinal cords and brains of SNS-GluA1–/– mice, 
verifying specificity of deletion in the DRG (Figure 1A and data 
not shown). Western Blot analysis on DRG, spinal cord, and brains 
of GluA1fl/fl mice and SNS-GluA1–/– mice further confirmed a DRG-
specific loss of GluA1 in SNS-GluA1–/– mice (Figure 1F). GluA1 
expression in the DRG was unchanged in SNS-GluA2–/– mice (Sup-
plemental Figure 2C).
SNS-GluA2–/– mice showed a similar profile of Cre-mediated 
gene deletion of GluA2 (Figure 1B). An antibody that has been 
widely used to characterize GluA2 expression (but which recog-
nizes mouse GluA2 and GluA3) showed that anti-GluA2/3 immu-
noreactivity was markedly reduced, but not lost, in small-diam-
eter DRG neurons in SNS-GluA2–/– mice (typical examples are 
shown in Figure 1B and mean summary of size frequency analysis 
is shown in Figure 1D). A newly described commercial antibody, 
which recognizes recombinant GluA2, but not GluA3, revealed a 
loss of GluA2 in CGRP-positive or IB4-positive neurons of SNS-
GluA2–/– mice (Supplemental Figure 2, A and B) but not in those 
of SNS-GluA1–/– mice (Figure 1E and Supplemental Figure 1). Fur-
thermore, Western blot analysis with the same antibody yielded a 
band of the size expected for GluA2 in the DRG of GluA2fl/fl mice 
but not in SNS-GluA2–/– mice (Figure 1F). In contrast, the GluA2 
band was retained in the DRG of SNS-GluA1–/– mice (Supplemen-
tal Figure 2C). Finally, DRG derived from SNS-GluA1–/– mice and 
SNS-GluA2–/– mice did not show any changes in the expression of 
GluA2 and GluA1, respectively, ruling out compensatory changes 
in the expression of other GluR subunits upon conditional dele-
tion of GluA1 or GluA2 (Figure 1, A and B).
Normal development of DRG neurons and their peripheral and central affer-
ent connections in SNS-GluA1–/– and SNS-GluA2–/– mice. SNS-Cre–medi-
ated gene deletion in the DRG commences perinatally (E17.5–P0) 
(13), thus side-stepping potential embryonic developmental defects 
in early outgrowth and patterning of DRG afferents, which typically 
take place over E12.5–E14.5 in mice (17, 18). Nevertheless, we ascer-
tained that SNS-GluA1–/– mice and SNS-GluA2–/– mice do not show 
any obvious developmental defects in the spinal sensory-motor 
circuitry. The distribution of peptidergic (CGRP-expressing) and 
nonpeptidergic (IB4-binding) small-diameter neurons in the DRG 
and the pattern of their termination in the spinal dorsal horn was 
similar in adult SNS-GluA1–/– and SNS-GluA2–/– mice, as compared 
with that in GluA1fl/fl and GluA2fl/fl mice, respectively (Supplemen-
tal Figure 3A). Similarly, innervation of peripheral organs, such as 
the glabrous skin of the hind paw, was normal in these conditional 
mouse mutants, as revealed by immunohistochemistry for PGP9.5, 
a marker of peripheral nerves, and CGRP (Supplemental Figure 
3B). Finally, high-resolution microscopy revealed normal density of 
synapses between peptidergic (CGRP-expressing) and nonpeptider-
gic (IB4-binding) nociceptive afferents and PSD-95–positive puncta 
(representing postsynaptic aspects of glutamatergic synapses) in 
the spinal dorsal horns of SNS-GluA1–/– mice and SNS-GluA2–/– 
mice (Supplemental Figure 3C and see Supplemental Table 1 for 
quantification). We therefore concluded that SNS-GluA1–/– mice 
and SNS-GluA2–/– mice show normal development of spinal and 
peripheral sensory circuits.
Presynaptic inhibitory effects of AMPA at spinal synapses. To directly 
test the presence and function of AMPARs on central terminals 
of primary afferent fibers, we compared sensitivity of transmitter 
release to exogenous AMPA (120–250 nM) application in spinal 
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slices, as described by Lee et al. (9). Patch-clamp recordings in 
voltage-clamp mode were performed from a total of 43 lamina I 
and II neurons in slices derived from SNS-GluA1–/– mice, SNS-
GluA2–/– mice, and their respective control littermates. Glutama-
tergic monosynaptic excitatory postsynaptic currents (EPSCs) 
were evoked by dorsal root stimulation. In slices derived from all 
mouse populations, the application of AMPA consistently evoked 
a sustained increase in holding current, reflecting activation of 
postsynaptic AMPAR on the cell under study. Furthermore, EPSC 
peak amplitudes were significantly depressed by AMPA, with 
the percentage of inhibition varying among cells. Both effects of 
AMPA were rapidly reversible upon washout (Figure 2A). AMPA-
induced EPSC inhibition has been reported to represent a sum of 
both postsynaptic and presynaptic actions of AMPA (9). To assess 
presynaptic AMPAR activity in the different populations, we ana-
lyzed changes in the coefficient of variation (CV) of EPSC ampli-
tudes with AMPA application (19).
We constructed plots of the ratio of CV–2 (CV–2AMPA/CV–2control) as 
a function of the relative EPSC amplitude (EPSCAMPA/EPSCcontrol), 
where CV–2AMPA represents 1/coefficient of variation squared, mea-
sured during application of AMPA; CV–2control represents 1/coeffi-
cient of variation squared, obtained in control; and EPSCAMPA and 
EPSCcontrol represent mean amplitude of EPSCs, measured during 
AMPA application and in control, respectively, assuming that post-
synaptic changes produce a change in mean amplitude without 
affecting the CV values, whereas presynaptic modulation would 
be expected to alter both parameters (20). As a control for this 
analysis, we recorded from lamina II neurons under control bath 
conditions, but at 2 different holding potentials (–85 and –55 mV), 
to mimic a pure postsynaptic modulation. Mean amplitude 
decreased at –55 mV, while the CV value did not change (Figure 2B, 
n = 6). Conversely, lowering the concentration of extracellular cal-
cium from 2 mM to 1 mM caused both a decrease of mean ampli-
tude and a change of CV (Figure 2B, n = 7), as would be expected 
for a presynaptic modulation.
Using these analysis parameters, we then compared data from 
mutant mice with their respective littermate controls. In the GluA1fl/fl 
control group, 9 out of 10 neurons exhibited a presynaptic modula-
tion of glutamate release. In contrast, depression of EPSC ampli-
tude was not accompanied by a corresponding change of CV in 5 
out of 12 cells recorded from SNS-GluA1–/– mice, suggesting involve-
ment of a pure postsynaptic mechanism due to loss of presynaptic 
inhibition (Figure 2C). The mean ratio between CV (AMPA) and CV 
(control) was significantly lower in SNS-GluA1–/– mice as compared 
with that in GluA1fl/fl mice (Figure 2E), indicating that presynap-
tic modulation by AMPA was less effective in spinal slices derived 
from SNS-GluA1–/– mice. In contrast, all neurons recorded from 
GluA2fl/fl mice or from SNS-GluA2–/– mice exhibited changes of both 
CV and mean amplitude, suggesting the presence of presynaptic 
modulation (Figure 2D; n = 10 and 11, respectively). Furthermore, 
the mean ratio between CV (AMPA) and CV (control) was similar in 
SNS-GluA2–/– mice and GluA2fl/fl mice (Figure 2E). Taken together, 
these results suggest that GluA1-containing AMPARs are expressed 
near sites of transmitter release in primary sensory neurons and are 
involved in AMPA-induced depression of release from primary affer-
ent nerve terminals in the spinal dorsal horn.
Modulation of peripheral afferent responses to heat and capsaicin by 
GluA1. We then addressed how the loss of GluA1-containing 
AMPARs affects the peripheral functions of nociceptors in target 
organs, such as the skin. Using the skin-nerve preparation (21), we 
recorded the activation of identified nociceptors to noxious stim-
uli, such as heat or capsaicin (Figure 3, A and B). The proportion 
of C-mechanonociceptors and C-mechanoheat fibers (C-MHs) 
excited by 100 μM capsaicin was similar between SNS-GluA1–/– 
and GluA1fl/fl mice (Figure 3F). Importantly, however, capsaicin-
induced spiking in nociceptors was significantly reduced in SNS-
GluA1–/– mice compared with that in GluA1fl/fl mice (Figure 3, E and 
G). In contrast, C-MHs from SNS-GluA1–/– mice and GluA1fl/fl mice 
showed identical response characteristics to heat ramps applied 
to the receptive field. Thus, using a ramp and hold heat stimulus 
(ramp from 32°C to 52°C in 20 seconds hold at 52°C for 5 sec-
onds then ramp back to 32°C in 20 seconds), C-MHs displayed the 
same mean threshold temperature for the first and second spike 
(Figure 3, C and D). These data demonstrate that the magnitude of 
capsaicin-evoked excitation is reduced in C-nociceptors that lack 
GluA1-containing AMPARs; however, there is no change in sensi-
tivity to noxious heat.
Analysis of the contribution of GluA1 to basal excitability in nociceptors. 
Using the whole cell mode of the patch clamp technique, we then 
analyzed the membrane properties of isolated DRG neurons with 
the physiological and morphological properties of nociceptors 
(small cell size and humped action potential; refs. 21, 22). The rest-
ing membrane potential of DRG neurons measured from SNS-
GluA1–/– and GluA1fl/fl mice were not different (Figure 4A). We 
then used step current injections to measure the threshold current 
for initiating action potentials but found no difference between 
the 2 genotypes (Figure 4B). We went on to use a ramp current 
injection to measure the latency for the first spike as well as the 
input-output curve (number of spikes against injection current); 
none of these parameters differed between neurons isolated from 
Figure 1
Generation and characterization of mice lacking GluA1 or GluA2 
in Nav1.8-expressing neurons (nociceptors) of the DRG. (A) 
Immunohistochemistry with anti-GluA1, anti-Cre, and anti-GluA2/3 
antibodies on sections of the DRG, spinal dorsal horn, and forebrain 
(anterior cingulate cortex is shown) of control mice (GluA1fl/fl mice), 
nociceptor-specific GluA1 knockout mice (SNS-GluA1–/– mice), and 
mice globally lacking GluA1 (GluA1–/– mice). (B) Immunohistochemistry 
with an antibody recognizing GluA2 and GluA3 (anti-GluA2/3) and 
anti-GluA1 and anti-Cre antibodies on sections of the DRG, spinal 
dorsal horn, and forebrain of control mice (GluA2fl/fl mice), nociceptor-
specific GluA2 knockout mice (SNS-GluA2–/– mice), and mice globally 
lacking GluA2 (GluA2–/– mice). (A and B) Scale bars: 50 μm (DRG 
images); 100 μm (spinal cord and brain images). (C and D) Quantita-
tive size frequency analysis of DRG neurons immunoreactive against 
anti-GluA1 or anti-GluA2/GluA3 confirms that small-diameter neurons 
lose and large-diameter neurons maintain expression of the respec-
tive genetically targeted subunits in (C) SNS-GluA1–/– mice and (D) 
SNS-GluA2–/– mice. (C) In contrast, anti-GluA2/GluA3 immunoreactiv-
ity is maintained in SNS-GluA1–/– mice, and (D) anti-GluA1 is main-
tained in SNS-GluA2–/– mice. (E) Dual immunofluorescence quantita-
tive analysis of anti-GluA1 and anti-GluA2 with markers of peptidergic 
nociceptors (CGRP) and nonpeptidergic nociceptors (IB4) confirms 
a near complete loss of GluA1 in nociceptors of SNS-GluA1–/– mice 
and loss of anti-GluA2 in SNS-GluA2–/– mice. In C–E, y axes repre-
sent immunopositive cells represented as a percentage of all cells 
counted in corresponding DRG sections. *P < 0.05 as compared to 
corresponding flox control mice. (F) Western blot analyses confirm 
DRG-specific deletion of GluA1 or GluA2 in SNS-GluA1–/– and SNS-
GluA2–/– mice, respectively. Units for numbers in F are kDa. α-Tubulin 
represents a loading control.
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SNS-GluA1–/– and GluA1fl/fl mice (Figure 4, C–E). We also found no 
differences in the magnitude of macroscopic inward and outward 
currents measured in voltage-clamp mode between neurons taken 
from SNS-GluA1–/– and GluA1fl/fl mice (data not shown). Thus, a 
loss of GluA1-containing AMPARs does not elicit a general change 
in the excitability of nociceptive neurons.
Calcium permeability of AMPARs in nociceptive neurons. The density 
of calcium-permeable AMPARs over most areas of the central ner-
vous system is known to be low; moderate to high densities are only 
seen in specific areas and particular cell types (3–6). To address 
whether AMPARs expressed on peripheral nociceptive neurons are 
calcium permeable, we performed Fura-2–based calcium imaging 
on cultured DRG neurons derived from GluA1fl/fl and SNS-GluA1–/– 
mice. Because SNS-Cre–mediated target gene deletion only occurs 
in Nav1.8-expressing nociceptors, there was a need for live identi-
fication of nociceptive neurons in this heterogenous mix of DRG 
neurons. We therefore used Alexa Fluor 488–conjugated IB4 (IB4-
Fluor488) for live identification of nonpeptidergic small-diam-
eter nociceptive neurons, which constitute approximately 50% of 
nociceptors (Figure 4F; neurons dually labeled with Fura-2 and 
IB4-Fluor488 are indicated by arrowheads); a method for live label-
ing of peptidergic neurons specifically is not available. Application 
of AMPA (10 μM) in the presence of cyclothiazide (CTZ; 20 μM), 
an antagonist of AMPAR desensitization, produced typical 
Figure 2
Patch clamp analysis of AMPA-induced modulation of synaptic transmission between primary afferents and spinal dorsal horn neurons in SNS-
GluA1–/– and SNS-GluA2–/– mice and their control littermates, GluA1fl/fl and GluA2fl/fl mice. (A) Glutamatergic EPSCs recorded from a lamina II 
neuron obtained from a wild-type mouse. Application of AMPA (250 nM) caused a depression of EPSC, an increase of amplitude variability, and 
the appearance of some failures, which were reversed upon washing AMPA out. (B–D) Plot data showing the ratio of CV-2 as a function of relative 
EPSC amplitude. Each symbol represents 1 neuron. (B) Graph representing CV changes in control experiments (low extracellular calcium and 
change of holding potential) mimicking presynaptic and postsynaptic modulations, respectively. 1/CV2treatment/1/CV2control represents the ratio between 
1/coefficient of variation squared, obtained during treatment (either 1mM extracellular calcium or holding potential = –55 mV), and 1/coefficient of 
variation squared, measured in control (i.e., 2 mM extracellular calcium or holding potential = –85 mV). Itreatment/Icontrol represents the ratio between 
mean EPSC amplitude, measured during treatment (see above), and mean EPSC amplitude measured in control. (C and D) Effects of AMPA on 
EPSC amplitudes and CV values in wild-type,  GluA1fl/fl, and SNS-GluA1–/– mutant mice. A subpopulation of neurons from SNS-GluA1–/– mice exhib-
ited a pure postsynaptic modulation, since the CV remained constant in AMPA. 1/CV2AMPA/1/CV2control represents the ratio between 1/coefficient of 
variation squared, obtained during application of AMPA250 nM and 1/coefficient of variation squared, measured in control. IAMPA/Icontrol represents 
the ratio between mean EPSC amplitude, measured during AMPA application, and mean EPSC amplitude measured in control. (E) The ratio of CV 
in AMPA to CV in control is significantly lower in SNS-GluA1–/– mice, as compared with that in GluA1fl/fl mice (*P < 0.05, t test).
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increases in the ratio of Fura-2 fluorescence at 340/380 nm in 10 
out of 44 nociceptive neurons from GluA1fl/fl mice. In contrast, 
only 1 out of 46 neurons from SNS-GluA1–/– mice responded to 
AMPA plus CTZ (see Figure 4G for typical examples and Figure 4H 
for quantitative summary), although all neurons responded to KCl 
(Figure 4H). The proportion of nociceptive neurons responding to 
glutamate (3 mM) was significantly higher in GluA1fl/fl mice than 
that in SNS-GluA1–/– mice (P = 0.02; Figure 4H). Furthermore, the 
magnitude of calcium gradients evoked by glutamate was reduced 
by nearly 50% in SNS-GluA1–/– mice as compared with that in 
GluA1fl/fl mice (see Figure 4G for typical examples and Figure 4I 
for quantitative summary). In contrast, the magnitudes of calcium 
responses induced by KCl (Figure 4I) were comparable in neurons 
derived from GluA1fl/fl and SNS-GluA1–/– mice (P > 0.05). These 
results show that a considerable proportion of nociceptive neu-
rons express calcium-permeable AMPARs (at least 25%) and that 
GluA1-containing calcium-permeable AMPARs account for about 
50% of the calcium flux produced by the endogenous agonist glu-
tamate in nociceptors.
Specific deficits in acute nociceptive hypersensitivity upon DRG-specific 
loss of GluA1 but not GluA2. Behavioral testing revealed that a loss 
of GluA1 in nociceptors was specifically associated with marked 
changes in pain-related behavior. In contrast, SNS-GluA2–/– mice 
are indistinguishable from their control GluA2fl/fl littermates in all 
Figure 3
Electrophysiological analysis of peripheral nociceptive fiber responses to nociceptive stimuli in GluA1fl/fl mice and SNS-GluA1–/– mice. (A) Scheme 
of the skin-saphenous nerve preparation and the recording setup (see Methods for details). (B and C) Analysis of responses of C-mechanoheat 
nociceptors to heat ramps. (B) A typical example of spike activity in response to a heat ramp. T, temperature. (C) Average spike activity from a 
population of nociceptors. (D) The threshold temperature for evoking first and second spikes. (E–G) Analysis of responses of C-mechanoheat 
(C-MH) and C-mechano (CM) types of nociceptors to application of capsaicin (100 μM) to the receptive field in the skin. (E) Typical examples of 
capsaicin-evoked spikes in SNS-GluA1–/– and GluA1fl/fl mice. (F) Cumulative summary of the incidence of capsaicin-sensitive nociceptors. (G) 
Summary of the magnitude of capsaicin-evoked action potentials in nociceptors of SNS-GluA1–/– and GluA1fl/fl mice. No significant differences 
were seen between genotypes in C, D, and F. Two-way ANOVA for repeated measures revealed significant differences in the cumulative curves 
representing SNS-GluA1–/– and GluA1fl/fl mice (P < 0.001). *P < 0.05 for the time point indicated (post-hoc Bonferroni test).
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nociception tests used in this study (see Supplemental Figure 4). 
Acute withdrawal responses to pressure or to a heat ramp applied 
(using a plantar test or to constant heat at 50°C and 55°C) were 
not significantly altered in SNS-GluA1–/– mice as compared with 
those in GluA1fl/fl mice (Figure 5, A and B). However, acute noci-
fensive responses evoked by an intraplantar injection of capsaicin 
(Figure 5C) were markedly attenuated in SNS-GluA1–/– mice as 
compared with those in GluA1fl/fl mice, entirely consistent with 
our electrophysiological finding that capsaicin excites nocicep-
tors to a lesser extent in SNS-GluA1–/– mice (see Figure 3, E–G). 
Application of capsaicin to the skin has been reported to lead to 
a rapid release of glutamate from C-fibers (e.g., refs. 23, 24). We 
observed that subcutaneous pretreatment of wild-type mice with 
GYKI 52466 (5 nmol), a specific AMPAR antagonist, significantly 
Figure 4
Analysis of the basal excitability, activation properties, and calcium transients in the somata of nociceptive sensory neurons in SNS-GluA1–/– and 
GluA1fl/fl mice. (A) Average resting membrane potential in nociceptive neurons identified via small cell size and humped action potential. (B) 
Typical example of action potentials (APs) generated by step-wise increments of current injection (threshold) and the average threshold current 
required to evoke action potentials. (C) Typical examples of the nature and frequency of action potentials evoked by prolonged current injections. 
(D and E) Input-output curves representing (D) the average latency to spiking and (E) the number of spikes in response to graded current injec-
tions. In A–E, P > 0.05 between genotypes, 2-way ANOVA. (F) Typical examples of Fura-2–loaded dissociated DRG nociceptive neurons identi-
fied live via binding to IB4 (arrowheads). (G) Typical examples of traces of calcium transients represented as ratiometric change in fluorescence 
emission upon sequential excitation at 340 nm and 380 nm (F340/F380) prior to and after bath application of glutamate (3 mM), AMPA (10 μM) 
plus CTZ (20 μM), or KCl (25 mM, internal control). (H) Summary of the fraction of Fura-2–labeled IB4-positive DRG neurons responding to 
agonists (expressed as a percentage of total cells tested) over 9 to 10 independent culture experiments. (I) Average of peak ratiometric changes 
in cells that responded to glutamate and KCl in SNS-GluA1–/– mice (red bars) and GluA1fl/fl mice (black bars). (ΔF/F) X100 is the percentage 
increase of F340/F380 ratio over basal. *P < 0.05, ANOVA for random measures, Fisher’s post-hoc test.
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attenuated capsaicin-evoked nocifensive responses (P = 0.005; 
Figure 5D). Similar results were observed upon peripheral treat-
ment with 1-naphthyl acetyl spermine (1-NAS, 100 pml), which 
is postulated to function as a selective inhibitor of calcium-per-
meable AMPARs (25) (P = 0.01; Figure 5D). This suggests that 
capsaicin-induced glutamate release activates GluA1-containing 
AMPARs, leading to augmentation and prolongation of the cap-
saicin-evoked excitation of C-fibers. Similar to the effects of cap-
saicin, intraplantar formalin-evoked acute nocifensive responses 
(phase I) occurred to a markedly lesser extent in SNS-GluA1–/– mice 
than in GluA1fl/fl mice (Figure 5E). Interestingly, formalin-induced 
increases in the number of DRG neurons expressing the plastic-
ity-related molecules, phosphorylated ERK1/2 (26), occurred to a 
significantly lower level in SNS-GluA1–/– mice, as compared with 
GluA1fl/fl mice (Figure 5F), suggesting that plasticity evoked by 
persistent nociceptive inputs in peripheral nociceptive neurons 
requires GluA1-containing AMPARs. Consistent with the above, 
the phase II behavioral response to formalin, which reflects early 
inflammatory hypersensitivity, was also significantly attenuated 
in SNS-GluA1–/– mice as compared with that in GluA1fl/fl control 
mice (P = 0.04; Figure 5E).
Marked defects in the development and maintenance of chronic inflam-
matory mechanical hypersensitivity in SNS-GluA1–/– mice. We then 
addressed whether the manifestation of long-lasting inflamma-
tory pain is functionally linked to AMPARs localized on nocicep-
tors. Prior to inflammation, SNS-GluA1–/– mice and GluA1fl/fl mice 
demonstrated comparable response thresholds (Figure 6A) and 
response frequencies (data not shown) to von Frey hairs applied 
to the plantar surface. After intraplantar injection of CFA unilat-
erally in the hind paw, SNS-GluA1–/– mice developed paw edema, 
which was comparable to that shown by their respective control 
littermates (Supplemental Figure 5A). CFA-induced mechanical 
hypersensitivity was tested by applying graded punctuate pressure 
via von Frey hairs, and the minimum force that evoked withdraw-
Figure 5
Analysis of the contribution of peripheral AMPARs to the modulation of acute nociception and early nociceptive hypersensitivity. (A) Latency 
of paw withdrawal after application of noxious heat in form of infrared heat ramp (left) or constant temperature (right) and (B) threshold of paw 
withdrawal to mechanical stimuli applied via the dynamic aesthesiometer is normal in SNS-GluA1–/– mice. (C) SNS-GluA1–/– mice show reduced 
duration of acute nocifensive behaviors in seconds, upon hind paw intraplantar injection of 0.06% capsaicin (n = 7–15 mice per group; *P < 0.05). 
(D) Capsaicin-induced nocifensive behaviors in wild-type mice are reduced upon peripheral pretreatment with a pan-antagonist of AMPARs, 
GYKI 52466, or a specific antagonist of calcium-permeable AMPARs, 1-NAS (n = 5 mice per group; *P < 0.05). (E) SNS-GluA1–/– mice show 
reduced duration of acute nocifensive behaviors (phase I) as well as early inflammatory hypersensitivity (phase II), upon hind paw intraplantar 
injection of 1% formalin (n = 7–15 mice per group; *P < 0.05 as compared with GluA1fl/fl mice). (F) Quantification of neuronal activation 1 hour 
after intraplantar formalin injection by means of counting pERK-positive neurons in DRG sections of SNS-GluA1–/– and control mice (n = 7–15 
mice per group; *P < 0.05 as compared with the corresponding control mice). Data was analyzed via ANOVA for random measures, post-hoc 
Fischer’s test in E and F, and Student’s t test in A–D.
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Figure 6
Behavioral and electrophysiological analysis of hypersensitivity in SNS-GluA1–/– and GluA1fl/fl mice caused by intraplantar injection of CFA or 
glutamate (100 nmol). (A) Summary of response thresholds (defined as a force eliciting a response frequency of at least 40%), and a comparison 
of response frequencies in response to plantar von Frey hair application. (B) Changes in paw withdrawal latency (PWL) in response to infrared 
heat in the inflamed paw represented as the percentage decrease over the contralateral uninflamed paw. (A and B) *P < 0.05 as compared 
with the corresponding basal states; †P < 0.05 as compared with GluA1fl/fl mice; ANOVA for random measures, post-hoc Fisher’s test; n = 16 
per genotype. (C) Firing frequencies in response to pressure applied via a nanomotor (expressed in terms of displacement) in the skin-nerve 
preparation. After inflammation, C-mechanoceptors showed potentiated responses in GluA1fl/fl mice but not in SNS-GluA1–/– mice (*P < 0.05, 
repeated measures ANOVA over the whole curve; *P < 0.05 between the 2 genotypes at the indicated points, post-hoc Bonferroni; n = 10–20 
mice per group). (D) Peripherally administered GYKI 52466 as well as 1-NAS significantly blocked mechanical hypersensitivity, but not thermal 
hyperalgesia, evoked by intraplantar injection of glutamate. *P < 0.05 as compared with basal; †P < 0.05 as compared with glutamate plus vehicle 
group; n = 5 mice per group. All data points represent mean ± SEM.
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al responses toward at least 2 out of 5 applications of von Frey 
hairs was denoted as response threshold. Whereas GluA1fl/fl mice 
developed significant mechanical hypersensitivity (drop in von 
Frey hair threshold) at 4, 12, 24, and 48 hours after CFA injection 
as compared with their corresponding basal values (Figure 6A; 
ANOVA followed by Fisher’s test), the drop in the mechanical 
response threshold in SNS-GluA1–/– mice over basal values was 
not statistically significant (P > 0.05; Figure 6A). Furthermore, 
although von Frey thresholds in GluA1fl/fl mice and SNS-GluA1–/– 
mice under basal conditions were not significantly different from 
each other (P = 0.3, ANOVA followed by Fisher’s test), response 
thresholds at 4, 12, 24, and 48 hours were significantly different 
from each other (Figure 6A; ANOVA followed by post-hoc Fisher’s 
test). This was also evident when directly comparing the response 
frequencies to graded von Frey hairs between GluA1fl/fl mice and 
SNS-GluA1–/– mice; an example at 48 hours after CFA injection, 
a time of peak hyperalgesia, is shown in Figure 6A (P < 0.05 
between the 2 genotypes). In contrast to mechanical hyperalgesia, 
CFA-induced thermal hyperalgesia, which was calculated as per-
centage decrease in paw withdrawal latency in the inflamed paw 
over the uninflamed contralateral paw, developed in both SNS-
GluA1–/– mice and GluA1fl/fl mice (P < 0.05 as compared with basal; 
Figure 6B) to a similar level (P > 0.05 between genotypes). SNS-
GluA2–/– mice did not differ from their GluA2fl/fl littermates with 
respect to CFA-induced thermal and mechanical hypersensitivity 
(Supplemental Figure 4).
Nociceptors lacking GluA1-containing AMPARs do not show mechani-
cal sensitization upon peripheral inflammation. We directly studied the 
sensitivity of nociceptors to mechanical stimuli and inflammation-
induced changes thereof in SNS-GluA1–/– and GluA1fl/fl mice. Elec-
trophysiological recordings were made from A-δ and C-fibers in the 
saphenous nerve, and the mechanical stimuli consisted of a series 
of ascending displacement stimuli applied to the receptive field of 
single fibers. A-δ nociceptors (Supplemental Figure 6) and C-fibers 
(Figure 6C) showed comparable threshold and suprathreshold 
responses in naive adult SNS-GluA1–/– and GluA1fl/fl mice. Further-
more, conduction velocities were not different between 2 genotypes 
(Student’s t-test, P > 0.05; Supplemental Table 2). C-mechanocep-
tors from GluA1fl/fl mice demonstrated potentiated responses to 
suprathreshold displacement stimuli when tested at 4–6 hours after 
paw inflammation induced by injection of CFA (P < 0.05, repeated 
measures ANOVA; Figure 6C). In contrast, C-mechanoceptors in 
SNS-GluA1–/– mice did not show any significant sensitization to 
displacement stimuli after paw inflammation (P = 0.0117, repeated 
ANOVA on the 2 curves; Figure 6C). The 2 genotypes were signifi-
cantly different from each other at displacement values of 192 μm 
Figure 7
Analysis of arthritis-induced chronic pain hypersensitivity in GluA1fl/fl mice and SNS-GluA1–/– mice. (A) Summary of response thresholds (defined 
as a force eliciting a response frequency of at least 40%) to von Frey hair application prior to (basal) and up to 18 days after induction of kaolin-
induced unilateral knee arthritis in SNS-GluA1–/– mice (n = 12) and their GluA1fl/fl littermates (n = 12). Von Frey hairs were applied to the plantar 
surface of the hind paws ipsilateral and contralateral to the arthritic knee. (B) Systemic treatment with the AMPAR antagonist, GYKI 52466, once 
per day completely blocked the development and maintenance of mechanical hypersensitivity (ipsilateral values are shown) in GluA1fl/fl mice but 
not in SNS-GluA1–/– mice (n = 6 per group). (A and B) *P < 0.05 as compared with basal; †P < 0.05 as compared with GluA1fl/fl mice.
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(P < 0.05), 384 μm (P < 0.01), and 768 μm (P < 0.01, Bonferroni 
post-test). Although A-δ fibers showed a tendency for sensitization 
to mechanical stimulation in CFA-injected GluA1fl/fl mice, a repeat-
ed measures ANOVA analysis of the stimulus-response curves failed 
to reach statistical significance (Supplemental Figure 6).
Peripheral glutamate-evoked hyperalgesia. Intrigued by the observa-
tion that GluA1-containing AMPARs appeared to play a signifi-
cant role in inflammation-induced mechanical hyperalgesia, but 
not thermal hyperalgesia, we asked whether this generally applies 
to all AMPARs. We observed that acute mechanical hyperalgesia 
evoked by intraplantar injection of glutamate (100 nmol; 20 min-
utes after injection) tested via von Frey hair application to the paw 
was significantly attenuated by peripheral pretreatment with a 
selective AMPAR antagonist, GYKI 52466 (P = 0.03 for 0.16 g and 
0.6 g force; Figure 6D). In contrast, glutamate-induced acute ther-
mal hyperalgesia was not significantly affected by peripheral GYKI 
52466 (Figure 6D). Furthermore, glutamate-induced mechanical 
hypersensitivity in wild-type mice was blocked by peripherally 
administered 1-NAS, an inhibitor of calcium-permeable AMPARs, 
significantly at a dose of 100 pmol and completely at a dose of 
1 nmol (Figure 6D), whereas glutamate-induced thermal hyper-
algesia remained unaffected (Figure 6D, right). Importantly, 
1-NAS–induced blockade of glutamate-induced peripheral sensi-
tization was also observed in GluA1fl/fl (control) mice but not in 
SNS-GluA1–/– mice, indicating thereby that at these doses periph-
eral 1-NAS produced its effects by specifically blocking peripheral 
calcium-permeable AMPARs (Supplemental Figure 7).
Arthritis-induced centrally mediated mechanical hypersensitivity does 
not develop in SNS-GluA1–/– mice. We went on to analyze nocicep-
tive behavior in another clinically relevant model of chronic pain, 
namely unilateral knee-arthritis. This model is particularly use-
ful for studying central changes elicited by enhanced excitatory 
drive from the periphery into the spinal cord, because the primary 
hyperalgesia evoked in the injured knee is accompanied by sec-
ondary hyperalgesia in the ipsilateral and contralateral hind paws 
(ref. 27 and Figure 7A, left). As compared with control GluA1fl/fl 
mice, SNS-GluA1–/– mice also showed a significantly reduced drop 
in response thresholds to von Frey at the ipsilateral paw after knee 
injury (P < 0.05 at all time points except 4–5 days after induction 
of arthritis; Figure 7A) and a markedly reduced duration of chron-
ic hypersensitivity (Figure 7A). Furthermore, whereas GluA1fl/fl 
mice developed marked, long-lasting mechanical hypersensitivity 
in the contralateral paw after knee injury (Figure 7A, right), SNS-
GluA1–/– mice failed entirely to develop contralateral hyperalge-
sia. Importantly, intraperitoneal administration of GYKI 52466 
in this arthritis model completely blocked the development of 
mechanical hypersensitivity in GluA1fl/fl (control) mice but did 
not affect mechanical sensitivity in arthritic SNS-GluA1–/– mice 
(Figure 7B), showing thereby that protective effects of GYKI 52466 
are indeed mediated by GluA1-containing AMPARs in nocicep-
tors. The above differences did not arise from differences in the 
degree of inflammation across genotypes, because typical indica-
tors of arthritis-induced knee inflammation, such as an increase 
in knee circumference (Supplemental Figure 5C), increased syno-
vial levels of myeloperoxidase (Supplemental Figure 5D), and 
neutrophil invasion in the synovial membrane (immunoreactiv-
ity for GR1, arrowheads in Supplemental Figure 5E), occurred at 
comparable levels in GluA1fl/fl mice and SNS-GluA1–/– mice. Thus, 
injury-evoked central changes in the processing of nociceptive 
inputs were markedly attenuated upon a specific loss of GluA1 in 
peripheral nociceptive neurons, suggesting that GluA1-contain-
ing AMPARs contribute significantly to the excitatory drive from 
the periphery into the central nervous system.
In support of this hypothesis, we observed that glutamate release 
in the spinal dorsal horn after peripheral stimulation of nocicep-
tors via formalin was affected in SNS-GluA1–/– mice. Microdialysis 
catheters were chronically implanted through the spinal dorsal 
horns of SNS-GluA1–/– mice and GluA1fl/fl mice in vivo (schemati-
cally represented in Supplemental Figure 8A), and both geno-
types showed a significant increase of glutamate concentrations 
immediately after formalin injection (before versus maximum 
after formalin, P < 0.001 and P < 0.0027 for SNS-GluA1–/– and 
GluA1fl/fl mice) (Supplemental Figure 8B). Analysis of area under 
the concentrations versus time curves, which represents not only 
the maximum change but also the duration of increase in gluta-
mate concentration after stimulation, showed that GluA1fl/fl mice, 
but not SNS-GluA1–/– mice, exhibited a significant increase over 
baseline levels over the first 25 minutes after formalin injection; 
basal values of glutamate release were not significantly different 
between the 2 genotypes (Supplemental Figure 8C).
Peripheral GluA1-containing AMPARs as pharmacological targets to 
attenuate inflammatory pain? Although a few studies have reported 
antinociceptive effects with nonspecific antagonists of non-NMDA 
glutamate receptors (e.g., NBQX and CNQX; refs. 28–30), very little 
is known about the specific role of peripheral AMPARs. We there-
fore performed experiments in which GYKI 52466 was adminis-
tered to mice, either systemically (subcutaneous, 20 μmol/kg 
body weight) or peripherally (intraplantar hind paw injection, 5 nmol), 
immediately after and at 18 and 23 hours after unilateral CFA 
injection in the paw. In wild-type mice, peripheral administra-
tion of GYKI 52466 significantly attenuated the development of 
mechanical hyperalgesia when tested 24 hours after CFA injection 
and measured using the von Frey hair test (P < 0.05 as compared 
with basal; P < 0.05 as compared with CFA plus vehicle; von Frey 
thresholds are shown in Figure 8A). In contrast, peripheral GYKI 
52466 did not block the development of CFA-induced thermal 
hyperalgesia (P < 0.05 as compared with basal; Figure 8A). Similar 
to wild-type mice, GluA1fl/fl mice treated peripherally with GYKI 
52466 also showed markedly lower levels of mechanical hyperal-
gesia than vehicle-treated GluA1fl/fl mice. In contrast, SNS-GluA1–/– 
mice developed markedly lower levels of mechanical hyperalgesia 
than GluA1fl/fl mice, as judged by measuring response frequency 
to von Frey hair stimulation, and pretreatment with peripheral 
GYKI 52466 did not further reduce behavioral signs of mechanical 
hyperalgesia compared with those of untreated SNS-GluA1–/– mice 
(P < 0.05 as compared with basal; P < 0.05 as compared with the 
GYKI 52466–treated group of the same genotype; P < 0.05 between 
the genotype treated either with vehicle or GYKI 52466; Figure 8B). 
The same data is shown in Figure 8C in the form of an integration 
of responses with graded von Frey force (area under the curve). 
Similar results were obtained using a dynamic aesthesiometer 
to test mechanical sensitivity, and 2 routes of administration of 
GYKI 52466 were compared: GluA1fl/fl mice treated systemically or 
peripherally with GYKI 52466 developed less mechanical hyper-
algesia than vehicle-treated mice 24 hours after CFA injection; 
SNS-GluA1–/– mice demonstrated less mechanical hyperalgesia 
after CFA injection than GluA1fl/fl mice, and the antihyperalgesic 
effects of GYKI 52466 with both routes of administration were 
entirely lost in SNS-GluA1–/– mice (P < 0.05 as compared with 
the vehicle-treated GluA1fl/fl group; P < 0.05 as compared with the 
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Figure 8
Effects of peripheral application of a selective AMPAR antagonist (GYKI 52466, 5 nmol) and a selective antagonist of calcium-permeable 
AMPARs (1-NAS, 100 pmol, 1 nmol, and 41.6 nmol) on inflammatory hypersensitivity. (A) In wild-type mice, the CFA-induced drop in mechani-
cal response threshold (plantar von Frey) is attenuated by peripheral GYKI 52466 (left), whereas CFA-induced thermal hyperalgesia is not 
affected (right). *P < 0.05 as compared with basal values. †P < 0.05 as compared to vehicle group. (B and C) Curves representing (B) response 
frequencies to graded von Frey hair stimulation and (C) corresponding integral values in the presence of GYKI 52466 or vehicle. (D) Analysis 
of mechanical hypersensitivity in the same cohorts of animals as in B and C using a dynamic aesthesiometer. CFA-induced mechanical hyper-
sensitivity in the inflamed paw is represented as percentage decrease over the uninflamed paw. †P < 0.05 as compared with GYKI 52466 group; 
*P < 0.05 as compared to vehicle treated GluA1fl/fl group. (B and C) *P < 0.05 as compared with corresponding basal value; †P < 0.05 as compared 
with GYKI 52466 group; ‡P < 0.05 as compared with SNS-GluA1–/– mice in the same group (GYKI 52466/vehicle); ANOVA followed by Fisher’s 
post-hoc test, n = 6–10 mice per group. (E) Effects of peripheral injection of 1-NAS on basal nociceptive sensitivity and CFA-induced hypersensi-
tivity, expressed as shift in stimulus-response frequencies to plantar von Frey stimulation (left), the corresponding area under the curve (middle), 
and thermal hyperalgesia (right). 1-NAS dose-dependently attenuated CFA-induced mechanical hypersensitivity but not thermal hyperalgesia. 
*P < 0.05 as compared with corresponding basal value; †P < 0.05 as compared with the 1-NAS group; ANOVA followed by Fisher’s post-hoc 
test, n = 5–10 mice per group.
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vehicle-treated SNS-GluA1–/– group; Figure 8D). At doses that sig-
nificantly affect these pain-related behaviors, GYKI 52466 did not 
cause sedation or affect motor functions, as measured using the 
open-field test (Supplemental Figure 9).
Similarly, CFA-induced mechanical hyperalgesia, but not ther-
mal hyperalgesia, was dose-dependently attenuated when 1-NAS 
was administered peripherally to wild-type mice (as described above 
for GYKI 52466) (P < 0.05 as compared with basal; P < 0.05 as com-
pared with the 1-NAS–treated group; Figure 8E). Taken together, 
these results show that peripheral application of an AMPAR antag-
onist or a specific blocker of calcium-permeable AMPARs inhibits 
inflammatory mechanical hypersensitivity by blocking GluA1-con-
taining peripheral AMPARs, suggesting therapeutic relevance.
Discussion
It is well established that glutamate receptors in the central ner-
vous system serve key functions in regulating plasticity events that 
underlie chronic pain states (1). This study serves toward clarify-
ing the functional role of AMPARs in the peripheral arm of the 
pain pathway in physiological and inflammatory states and pro-
vides proof of principle for a therapeutic relevance of peripheral 
AMPARs. Importantly, we observed that selective deletion of indi-
vidual AMPAR subunits in nociceptors, which alters their composi-
tion and properties without ablating AMPARs function completely, 
elicited specific changes in the processing of particular nociceptive 
modalities and algogens at peripheral terminals of nociceptors, 
while contributing to depression of neurotransmitter release at the 
central terminals of nociceptors. The net in vivo result of this dif-
ferential nature of modulation at central and peripheral terminals 
of nociceptors clearly emerged as a pronociceptive, sensitizing role 
for GluA1-containing AMPARs in inflammatory hyperalgesia.
Hypersensitivity to mechanical stimuli represents one of the 
most debilitating and clinically relevant manifestations of patho-
logical pain (1), which is why the finding that the composition and 
properties of peripheral AMPARs critically regulate mechanisms of 
mechanical hypersensitivity is very intriguing. Electrophysiological 
recordings in single nerve fibers showed that C-nociceptors in SNS-
GluA1–/– mice fail to sensitize toward mechanical stimuli in inflamed 
tissues, although they responded normally under basal physiologi-
cal conditions. These findings were corroborated by behavioral anal-
yses in SNS-GluA1–/– mice and with pharmacological tools, which 
consistently showed that blockade or loss of function of GluA1-con-
taining AMPARs in peripheral nociceptors inhibits inflammatory 
mechanical hyperalgesia. Interestingly, this pertained not only to 
primary hyperalgesia but also to secondary mechanical hyperalge-
sia, a centrally maintained process (1), which was reduced in mag-
nitude as well as in duration in mice lacking peripheral GluA1. This 
suggests that the GluA1-mediated increase in activity of peripheral 
nociceptors is causally linked to a potentiation of excitatory drive 
into the spinal cord, which would thereby facilitate central plasticity 
processes involved in secondary hyperalgesia.
Extrapolating from the excitatory nature of AMPARs in basal syn-
aptic transmission at central synapses (2), one mechanistic expla-
nation could be that peripheral GluA1-containing AMPARs con-
tribute to the overall excitability of nociceptors. This is conceivable 
because a deletion of GluA1 can reduce AMPAR-mediated currents 
to some extent (3). However, several observations argue against this 
hypothesis. First, no differences were seen between SNS-GluA1–/– 
mice and control mice, with respect to the resting membrane 
potential and threshold currents for evoking action potentials in 
patch-clamp recordings on the somata or basal response properties 
of peripheral nerves in the skin-nerve preparation. Furthermore, 
a change in general excitability of nociceptors would be expected 
to affect basal nociception in vivo and reduce hyperalgesia to all 
modalities of nociception, neither of which was reflected in behav-
ioral phenotype of SNS-GluA1–/– mice. We conclude therefore that 
GluA1-containing AMPARs do not generally regulate the excitabil-
ity of nociceptors. Rather, our observations suggest that GluA1-
containing AMPARs specifically regulate the strength and duration 
of algogen-induced excitation of nociceptors. In this context, the 
finding that peripheral AMPARs modulate responsivity to capsa-
icin is particularly interesting, because it represents low frequency, 
persistent activation of nociceptors, such as that induced by inflam-
matory mediators, including TRPV1 agonists, such as lipids and 
protons (31, 32). In contrast to phasic, short-lasting thermal and 
mechanical nociceptive stimuli, capsaicin evokes responses that are 
persistent, long-lasting, and associated with repetitive spiking of 
nociceptors, and capsaicin application is known to evoke a rapid 
release of glutamate from activated C-fibers in the skin (23, 24). 
Taken together with our observation that inhibition of peripheral 
AMPARs significantly attenuated capsaicin-evoked nocifensive 
behaviors, this suggests that capsaicin-induced glutamate release 
augments the magnitude and duration of the capsaicin response 
by recruiting peripheral AMPARs. This can explain why responses 
to algogens, which repetitively activate and sensitize nociceptors, 
are modulated by changes in peripheral AMPARs, whereas basal 
nociceptive sensitivity to acute heat and mechanical is not.
The observations that a large population of AMPARs in nocicep-
tors are permeable to calcium in wild-type mice and that reduc-
ing calcium permeability (e.g., in SNS-GluA1–/– mice or blockade 
with 1-NAS), but not increasing calcium permeability (e.g., in 
SNS-GluA2–/– mice), affects inflammatory hyperalgesia suggest 
that basal calcium flux via AMPARs in nociceptors may be the 
key determinant of inflammation-induced changes in nociceptor 
activation. Moreover, the observation that global GluA2 knock-
out mice, but not SNS-GluA2–/– mice, showed exaggerated noci-
ceptive hyperexcitability (6) suggests a larger contribution of cen-
trally expressed GluA2-containing AMPARs toward modulation 
of sensitization processes. In inflamed tissues, algogen-induced 
release of glutamate and the ensuing activation of calcium-per-
meable AMPARs would lead to an enhanced calcium influx into 
nociceptors and thereby engage downstream calcium-dependent 
mechanisms that tend to increase action potential firing in the 
presence of algogens. In this context, a number of calcium-depen-
dent protein kinases have been described, which serve to sensitize 
downstream receptors and channels, thereby enhancing excit-
ability (32). This model can also explain why baseline excitability 
of nociceptors is not altered in SNS-GluA1–/– mice (see above), as 
such amplification mechanisms mediated by GluA1-containing 
AMPARs would only operate in conditions of inflammation when 
algogenic chemicals are present.
Unlike mechanical hyperalgesia, inflammatory thermal hyperal-
gesia was not affected in SNS-GluA1–/– mice. It has been proposed 
that TRPV1-expressing neurons, rather than the TRPV1 channel 
itself, are critical for heat sensitivity (31–34), and, per se, it cannot 
be ruled out that some TRPV1-expressing neurons are not targeted 
by the SNS-Cre mouse line used in this study. However, the obser-
vation that peripheral application of GYKI52466 or 1-NAS, which 
should similarly affect all sensory fibers innervating the injected 
zone, showed similar effects suggests that differences in types of 
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sensory neurons affected by the genetic manipulation may not 
fully account for the above observations. Furthermore, previous 
studies have reported that much higher concentrations of periph-
erally applied glutamate are required to evoke thermal hyperalgesia 
than mechanical hyperalgesia (e.g., ref. 35). Furthermore, previous 
studies have suggested that metabotropic glutamate receptors are 
stronger modulators of mechanisms governing thermal hyperalge-
sia than ionotropic glutamate receptors (36, 37).
Although there is compelling ex vivo evidence for a role for pre-
synaptic AMPARs on central terminals in inhibiting evoked trans-
mission onto spinal neurons (9), the net change in excitation levels 
in the spinal dorsal horn and the in vivo relevance of this phenom-
enon are unclear. Here, we observed that although AMPA-induced 
inhibition of evoked transmission on spinal neurons was partially 
reduced in SNS-GluA1–/– mice, these mice did not show increased 
pain-related behavior, suggesting that presynaptic modulation via 
GluA1-containing AMPARs on spinal terminals of primary affer-
ents may not play an important role in nociception in vivo. In the 
light of this dual modulation of nociceptor function by AMPARs, 
the level of glutamatergic tone may be a key determinant of how 
AMPARs affect nociceptor excitation. This is suggested by our 
observations that phenotypic differences between AMPAR mutant 
and control mice come about only in states associated with 
increased glutamatergic tone, e.g., following peripheral inflamma-
tion or repetitive activation of nociceptors via formalin or capsa-
icin. Mechanistically, this may not only result from the peripheral 
mechanisms discussed above but also from the phenomenon of 
dorsal root reflexes (DRRs), which are centrally triggered action 
potentials evoked by depolarization of spinal terminals of primary 
afferents (38). DRRs have been reported to occur in inflammatory 
pain states and contribute to neurogenic inflammation (11, 38). 
Besides GABA-A receptors, non-NMDA glutamate receptors have 
been shown to contribute to DRRs (11, 38). It is conceivable there-
fore that the availability of the endogenous agonist directly influ-
ences the relative contributions of central and peripheral GluA1-
containing AMPARs and determines whether antinociceptive or 
pronociceptive outcomes prevail.
In this context, it is interesting to note that in pathophysiologi-
cal states, glutamate levels also rise markedly in peripheral tissues. 
For example, in addition to efferent release from activated primary 
afferents, invading macrophages, and serum from leaky blood ves-
sels, Schwann cells as well as keratinocytes can release glutamate in 
inflamed tissue (11). Glutamate concentrations have been reported 
to rise dramatically in synovial fluid taken from arthritic patients 
(39), and the expression of AMPAR subunits in peripheral nerves is 
increased in inflamed tissues (11), thereby indicating agonist avail-
ability for activation of peripheral AMPARs in pathophysiological 
states. However, under these circumstances, it is to be expected 
that the concentration of glutamate in inflamed or injured tissue 
remains persistently elevated, in contrast to synaptically released 
glutamate, which is rapidly cleared away from the vicinity of syn-
aptic glutamate receptors. Because native AMPARs exhibit rapid 
desensitization in the sustained presence of glutamate (40), this 
raises doubts about the extent to which AMPARs on peripheral 
nociceptors can stably influence nociceptor function upon pro-
longed exposure to glutamate. However, in cultured DRG neurons, 
AMPARs have been suggested to contribute more dominantly to 
glutamate-induced action potentials and steady-state depolariza-
tion and recover from desensitization more quickly than kainate 
receptors (41). Furthermore, diverse factors, such as RNA editing 
at the R/G site, alternative splicing of the flip and flop module, and 
heterogeneity in the composition of AMPAR/TARP complexes, are 
known to affect AMPAR desensitization recovery rates (42).
In summary, the results of this study demonstrate an important 
contribution of GluA1-containing calcium-permeable AMPARs 
expressed in the peripheral nervous system in modulating the activa-
tion properties of nociceptive neurons in response to algogens or in 
an inflammatory milieu. Furthermore, GluA1-containing AMPARs 
can control the inflow of nociceptive impulses from the periphery 
into the central nervous system and thus impact both peripheral 
and central hyperexcitability processes. These results provide a basis 
for developing novel pharmacological approaches targeting GluA1-
containing AMPARs in the periphery, which may enable alleviating 
inflammatory pain devoid of central side effects.
Methods
Details on methods are given in the Supplemental Methods.
Genetically modified mice. Homozygous mice carrying the floxed alleles (i.e., 
key loci flanked by loxP sites) for the mouse Gria1 locus encoding GluA1 
(GluA1fl/fl mice; ref. 15) and the mouse Gria2 locus encoding GluA2 (GluA2fl/fl 
mice; ref. 16) were crossed with SNS-Cre mice (14), which express the Cre 
recombinase under the influence of the mouse Scn10a promoter (encoding 
Nav1.8) to obtain litters consisting of GluA1fl/flSNS-Cre+ mice (referred to 
herein as SNS-GluA1–/– mice) and GluA1fl/fl mice (control littermates). Simi-
larly, GluA2fl/fl mice were crossed with SNS-Cre mice to obtain litters consist-
ing of GluA2fl/flSNS-Cre+ mice (referred to herein as SNS-GluA2–/– mice) and 
GluA2fl/fl mice (control littermates). Mice of all genotypes were individually 
backcrossed into the C57BL/6 background for more than 8 generations 
before being crossed with each other. In all experiments, littermates were 
strictly used to control for genetic effects of the background.
Immunohistochemistry. Immunohistochemistry was performed using 
standard protocols and the following antibodies: rabbit polyclonal anti-
GluA2/3 and anti-GluA1 antisera (both from Chemicon International); 
rabbit polyclonal anti-CGRP antiserum (ImmunoStar); rabbit anti-phos-
pho-p44/42 MAP Kinase (Thr202/Tyr204; pERK) antibody (Cell Signal-
ing Technology); and an anti-Cre (69050, Novagen). Synaptic contacts of 
primary afferents in the spinal dorsal horn were analyzed on Vibratome 
sections as described before (7) using a rabbit PSD-95 antibody (a gift from 
M. Watanabe, Hokkaido University School of Medicine, Sapporo, Japan; 
ref. 43). Neutrophils were labeled in frozen sections of intraarticular syno-
vial membrane of the mouse knee using a rat anti–Gr-1 (clone RB6-8C5, 
catalog 553125, BD Pharmingen; ref. 44).
Behavioral analysis. All animal use procedures were reviewed and approved 
by the local governing body (Regierungspräsidium Karlsruhe, Germany). 
All behavioral measurements were done in awake, unrestrained, and age-
matched adult (more than 3-month-old) mice of both sexes by individuals 
who were blinded to the genotype of the mice being analyzed. Mice were accli-
matized to the experimental setups several times before the analysis. Noci-
ceptive testing in mouse models of acute and chronic pain was performed as 
described in detail previously (refs. 6, 14, and Supplemental Methods).
Application of drugs. All chemicals were obtained from Sigma-Aldrich, except 
bicuculline, SYM 2081, and AMPA, which were obtained from Tocris Cook-
son Ltd. Mice were injected with GYKI 52466 and 1-NAS dissolved in DMSO 
and PBS, respectively. Subcutaneous injections of 20 μmol/Kg body weight of 
GYKI 52466 and intraplantar injections of GYKI 52466 (5 nmol) and 1-NAS 
(0.1, 1, and 41.6 nmol) were done in a volume of 20 μl each, under light ether 
anaesthesia lasting for 30 seconds to 1 minute. In the CFA model, GYKI 
52466 and 1-NAS were administered immediately after and at 18 hours and 
23 hours after unilateral hind paw injection of CFA. No effects were observed 
with injections of vehicle only on nociceptive withdrawal responses.
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Skin-nerve preparation and single-fiber recordings. Single-nerve recordings 
were performed from nerve fibers identified on the basis of response prop-
erties, using the saphenous nerve-paw skin preparation as described in 
detail previously (refs. 21, 22, and Supplemental Methods).
Analysis of glutamate levels in the spinal cord. A microdialysis-based method 
was used to determine the change in glutamate levels in the spinal dorsal 
horn of adult mice after intraplantar injection of formalin as described 
previously (ref. 45 and Supplemental Methods).
Calcium imaging from cultured DRG neurons. DRG neurons were dissociated 
from (6- to 8-week-old) mice and loaded 24–48 hours later with Fura-2 
(10 μM) and Alexa 488–conjugated IB4-Fluor (10 μg/ml; Molecular Probes) 
for live identification of small-diameter neurons. Calcium signals were 
recorded at a rate of 1 Hz, and F340/380 ratios were calculated as described 
previously (ref. 46 and Supplemental Methods).
Patch-clamp recordings. Patch-clamp recording in whole-cell configura-
tion was performed on visually identified lamina I and II neurons at 
room temperature in spinal slices prepared from mice at P15–P21 in 
response to dorsal root stimulation (50–500 μA, 0.1 ms) as described in 
ref. 9 (Supplemental Methods). Patch-clamp recordings were done on 
dissociated DRG neurons 24 hours after preparation as described in Sup-
plemental Methods. For determination of nociceptors, action potentials 
were evoked by repetitive 80 ms current injections, increasing from 20 pA 
to 400 pA in increments of 20 pA. The amount of current required for 
the first action potential was measured as threshold current. For excit-
ability measurements, a 2-second current ramp, ranging from 200 pA 
to 1,000 pA, was injected to the cell soma.
Statistics. All data are presented as mean ± SEM. The 2-tailed Student’s 
t-test or the ANOVA for random measures followed by post-hoc Fisher’s 
least significant difference test were used to determine statistically signifi-
cant differences (P ≤ 0.05).
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